Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036491 · ClinicalTrials.gov registry record · Phase 1
Anti-CD20 in Systemic Lupus Erythematosus
A Phase 1 study of Lupus Erythematosus, Systemic, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT00036491 is a Phase 1 study of Lupus Erythematosus, Systemic that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 24 participants, below the 203-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00036491, a Phase 1 study of Lupus Erythematosus, Systemic, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the safety and effectiveness of rituximab (anti-CD20) in treating systemic lupus erythematosus (SLE). White blood cells in the body called B cells give off substances that are active in promoting SLE disease. Researchers have found that anti-CD20 can block production of these substances in another disease. This study explores whether anti-CD20 will also be safe in people with SLE and whether it may be effective in treating SLE.
Conditions Studied
Interventions
- DRUG Rituximab
Study Locations (3)
Colorado
- University of Colorado - Denver
New York
- University of Rochester - Rochester
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2001-01 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036491
The ClinicalTrials.gov registry entry for NCT00036491 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 203-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (88% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 1 intervention - of which Rituximab is the first listed.
NCT00036491 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00036491 about?
NCT00036491 is a clinical study titled "Anti-CD20 in Systemic Lupus Erythematosus". The purpose of this study is to determine the safety and effectiveness of rituximab (anti-CD20) in treating systemic lupus erythematosus (SLE). White blood cells in the body called B cells give off substances that are active in promoting SLE disease. Researchers have found that anti-CD20 can block ...
What is the current status of trial NCT00036491?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2001-01. Estimated completion is 2006-01.
What conditions does trial NCT00036491 study?
This clinical trial studies the following conditions: Lupus Erythematosus, Systemic.
What interventions are being tested in trial NCT00036491?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00036491?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00036491 being conducted?
This trial has 3 study locations across Colorado, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Erythematosus, Systemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
COMPLETED · Phase 1
-
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
COMPLETED · Phase 1
-
Phase Ib Study of SC Milatuzumab in SLE
COMPLETED · Phase 1
-
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.